Theleme Partners LLP Has $303.82 Million Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Theleme Partners LLP increased its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 1.0% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 7,306,861 shares of the company’s stock after acquiring an additional 72,028 shares during the quarter. Moderna accounts for 20.4% of Theleme Partners LLP’s portfolio, making the stock its biggest position. Theleme Partners LLP’s holdings in Moderna were worth $303,819,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Wilmington Savings Fund Society FSB grew its holdings in Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after buying an additional 587 shares in the last quarter. Compass Planning Associates Inc bought a new stake in Moderna during the fourth quarter worth $37,000. Venturi Wealth Management LLC grew its holdings in Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after buying an additional 664 shares in the last quarter. Crowley Wealth Management Inc. bought a new stake in Moderna during the fourth quarter worth $41,000. Finally, Itau Unibanco Holding S.A. grew its holdings in Moderna by 51.2% during the fourth quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company’s stock worth $42,000 after buying an additional 343 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Barclays decreased their price target on Moderna from $45.00 to $40.00 and set an “equal weight” rating for the company in a report on Friday, May 2nd. JPMorgan Chase & Co. decreased their price target on Moderna from $40.00 to $33.00 and set an “underweight” rating for the company in a report on Friday, March 21st. Citigroup assumed coverage on Moderna in a research note on Thursday, March 13th. They issued a “neutral” rating and a $40.00 price objective for the company. William Blair restated a “market perform” rating on shares of Moderna in a research note on Thursday, April 17th. Finally, Bank of America reduced their price objective on Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a research note on Tuesday, February 11th. Four analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Moderna has a consensus rating of “Hold” and a consensus price target of $53.95.

Moderna Stock Performance

MRNA stock opened at $24.86 on Friday. The company has a market capitalization of $9.61 billion, a price-to-earnings ratio of -2.68 and a beta of 1.99. Moderna, Inc. has a fifty-two week low of $23.15 and a fifty-two week high of $170.47. The stock has a fifty day moving average of $27.87 and a 200-day moving average of $35.44.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, topping the consensus estimate of ($2.92) by $0.40. The company had revenue of $108.00 million during the quarter, compared to the consensus estimate of $130.35 million. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. The firm’s quarterly revenue was down 35.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($3.07) EPS. Equities analysts predict that Moderna, Inc. will post -9.61 EPS for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.